Seltorexant

Seltorexant (JNJ-42847922, MIN-202) is a selective, high-affinity antagonist of the orexin-2 receptor (OX2R) and the first selective 2-SORA to advance through Phase 3 clinical trials for major depressive disorder (MDD) with insomnia symptoms. The compound exhibits approximately 100-fold selectivity for OX2R over OX1R and negligible affinity for other receptors, transporters, or ion channels in a panel of 50 assays, a selectivity profile that distinguishes it mechanistically from the dual orexin receptor antagonists (DORAs) suvorexant, lemborexant, and daridorexant approved for primary insomnia. Pharmacokinetics are characterized by rapid oral absorption (median time to maximum plasma concentration 0.3 to 1.5 hours), a short elimination half-life of approximately 2 to 3 hours, and metabolism predominantly through cytochrome P450 3A4, producing a pharmacokinetic profile suited to bedtime administration with minimal next-day residual effects. Preclinical pharmacology in rodent models demonstrated dose-dependent increases in non-rapid eye movement (NREM) sleep duration, reduced sleep onset latency, attenuation of stress-induced adrenocorticotropic hormone (ACTH) release, suppression of hypothalamic-pituitary-adrenal (HPA) axis activation, and absence of effects on dopaminergic reward pathways or motor coordination. The specificity of these effects for OX2R was confirmed by the absence of activity in OX2R knockout mice. Brain penetration and receptor occupancy were confirmed by positron emission tomography imaging in rats and by in vivo competitive radioligand binding studies. The clinical evidence base spans Phase 1 through Phase 3 development. The Phase 1b study in 47 patients with MDD (Recourt et al. 2019) demonstrated statistically significant improvement in core depressive symptoms on the Hamilton Depression Rating Scale (HDRS17) and HAM-D6 subscale compared to placebo at 20 mg daily for 10 to 28 days, with concordant changes in sleep electroencephalography spectral power. The Phase 2b adaptive dose-finding study (Savitz et al. 2021) in 283 patients with MDD and inadequate response to SSRI or SNRI therapy reported statistically significant improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score, MADRS-6 core symptom subscale, Insomnia Severity Index, and PROMIS Sleep Disturbance at the 20 mg dose, with response rates of 41.0 percent versus 28.5 percent on placebo and remission rates of 29.5 percent versus 19.0 percent. The pivotal Phase 3 MDD3001 trial achieved its primary and all secondary endpoints, with seltorexant 20 mg adjunctive to SSRI or SNRI producing a statistically significant least-squares mean difference from placebo of negative 2.6 points on MADRS total score at day 43 (p = 0.007) and significant improvement in PROMIS Sleep Disturbance (negative 3.7, p < 0.001). The Phase 3 MDD3005 active-comparator study against quetiapine extended-release demonstrated a numerically higher response rate for seltorexant (57.4 percent versus 53.4 percent) that did not reach statistical significance, but with substantially fewer adverse events, lower somnolence incidence (6 percent versus 24 percent), and markedly less weight gain (0.5 kg versus 2.1 kg over 26 weeks). A separate monotherapy Phase 1b study (2024) in 128 MDD patients demonstrated antidepressant activity independent of adjunctive SSRI or SNRI use. The compound is well tolerated across the clinical program. The most common treatment-emergent adverse events are headache, somnolence, and nausea at incidences comparable to placebo. No deaths, serious treatment-emergent adverse events, clinically significant cardiovascular changes, or suicidal behavior events have been reported in the seltorexant treatment arms. No cataplexy has been observed. The compound does not produce conditioned place preference in mice, does not increase extracellular dopamine release in rat nucleus accumbens, and does not impair motor coordination at sleep-promoting doses, supporting a favorable abuse liability and safety profile relative to benzodiazepines and Z-drugs. Seltorexant has not yet received regulatory approval in any jurisdiction. Phase 3 clinical trials for adjunctive MDD with insomnia symptoms are ongoing, and Phase 2 investigation for primary insomnia and Alzheimer's disease is in progress. This monograph reviews the chemistry, synthesis, molecular pharmacology, pharmacokinetics, preclinical and clinical evidence base, sourcing and handling, stack interactions, adverse-event profile, and a comparative assessment of five orexin receptor antagonist candidates against seltorexant on five competency standards.